Such a combination therapy is even more timely in the perspective of a revival of the role of blood cells—leukocytes and platelets—in AD pathogenesis and the role of inflammasomes in neuroimmune and neurodegenerative diseases, targeting leukocytes and platelets potently by IFN and the inflammasome by potent anti-inflammatory JAK1-2 inhibition—ruxolitinib—or monoclonal antibodies targeting IL-1beta or IL-6 [70]. This evidence concerns the gene IFNA1 and neurodegenerative disease.